AUSTRALIANS with small cell lung cancer (SCLC), biliary tract cancer (BTC), juvenile idiopathic arthritis (JIA) and Crohn's disease will now have access to new treatment options through the PBS.
Keytruda (pembrolizumab) will be expanded on the PBS to treat early-stage triple-negative breast cancer.
Imfinzi (durvalumab) will be expanded for patients with extensive stage SCLC and advanced BTC.
Xeljanz (tofacitinib) will be expanded to provide an oral treatment for JIA, and Rinvoq (upadacitinib) will be expanded to treat patients with Crohn's disease.
The above article was sent to subscribers in Pharmacy Daily's issue from 15 Dec 23
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 15 Dec 23
